HER2 Support Group Forums - View Single Post - Ki67 Level 2 Weeks After Starting Arimidex Predicts Breast Cancer Relapse

Montana · 06-23-2006, 05:39 PM

Did your doctor ever discussed KI-67 with you? Has anyone ever had their KI-67 tested 2 weeks after starting Arimidex? Sue

http://www.medpagetoday.com/2005Meet...eeting/tb/2306
"An increase in Ki67 of 2.7-fold -- analyzed at the two-week mark -- results in a doubling of the risk of relapse, Mitchell Dowsett, Ph.D., of London's Royal Marsden Hospital reported at the San Antonio Breast Cancer Symposium. Differences in levels of the molecule measured before the start of treatment were not predictive, he said.

The magnitude of the hazard ratio was greater than that for tumor size in a multivariate analysis of 56 patients enrolled in the IMPACT study, Dr. Dowsett said:

For Ki67, the hazard ratio for relapse was 2.01 (with a 95% confidence interval of 1.28 to 3.15) for every 2.7-fold increase in the level two weeks after starting Arimidex treatment.
For tumor size, the hazard ratio for relapse was 1.67 (with a 95% confidence interval of 1.35 to 2.6) for every centimeter increase in diameter.

Ki67 is an indicator of cell proliferation rate and is already used to define the aggressiveness of late-stage breast cancer."

06-23-2006, 05:39 PM	#1
Montana Senior Member Join Date: Sep 2005 Posts: 161	Ki67 Level 2 Weeks After Starting Arimidex Predicts Breast Cancer Relapse Did your doctor ever discussed KI-67 with you? Has anyone ever had their KI-67 tested 2 weeks after starting Arimidex? Sue http://www.medpagetoday.com/2005Meet...eeting/tb/2306 "An increase in Ki67 of 2.7-fold -- analyzed at the two-week mark -- results in a doubling of the risk of relapse, Mitchell Dowsett, Ph.D., of London's Royal Marsden Hospital reported at the San Antonio Breast Cancer Symposium. Differences in levels of the molecule measured before the start of treatment were not predictive, he said. The magnitude of the hazard ratio was greater than that for tumor size in a multivariate analysis of 56 patients enrolled in the IMPACT study, Dr. Dowsett said: For Ki67, the hazard ratio for relapse was 2.01 (with a 95% confidence interval of 1.28 to 3.15) for every 2.7-fold increase in the level two weeks after starting Arimidex treatment. For tumor size, the hazard ratio for relapse was 1.67 (with a 95% confidence interval of 1.35 to 2.6) for every centimeter increase in diameter. Ki67 is an indicator of cell proliferation rate and is already used to define the aggressiveness of late-stage breast cancer."